IL263179A - Combination therapies with farnesoid x receptor (fxr) modulators - Google Patents

Combination therapies with farnesoid x receptor (fxr) modulators

Info

Publication number
IL263179A
IL263179A IL263179A IL26317918A IL263179A IL 263179 A IL263179 A IL 263179A IL 263179 A IL263179 A IL 263179A IL 26317918 A IL26317918 A IL 26317918A IL 263179 A IL263179 A IL 263179A
Authority
IL
Israel
Prior art keywords
farnesoid
fxr
modulators
receptor
combination therapies
Prior art date
Application number
IL263179A
Other languages
English (en)
Hebrew (he)
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of IL263179A publication Critical patent/IL263179A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL263179A 2016-05-25 2018-11-21 Combination therapies with farnesoid x receptor (fxr) modulators IL263179A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341487P 2016-05-25 2016-05-25
US201662341482P 2016-05-25 2016-05-25
PCT/US2017/034564 WO2017205684A1 (en) 2016-05-25 2017-05-25 Combination therapies with farnesoid x receptor (fxr) modulators

Publications (1)

Publication Number Publication Date
IL263179A true IL263179A (en) 2018-12-31

Family

ID=60412964

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263179A IL263179A (en) 2016-05-25 2018-11-21 Combination therapies with farnesoid x receptor (fxr) modulators

Country Status (13)

Country Link
US (1) US20200397798A1 (cg-RX-API-DMAC10.html)
EP (1) EP3463373A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019517478A (cg-RX-API-DMAC10.html)
KR (1) KR20190040936A (cg-RX-API-DMAC10.html)
CN (1) CN109843298A (cg-RX-API-DMAC10.html)
AU (1) AU2017270221A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018073460A2 (cg-RX-API-DMAC10.html)
CA (1) CA3025007A1 (cg-RX-API-DMAC10.html)
IL (1) IL263179A (cg-RX-API-DMAC10.html)
MX (1) MX2018014024A (cg-RX-API-DMAC10.html)
RU (1) RU2018145776A (cg-RX-API-DMAC10.html)
SG (2) SG11201810290WA (cg-RX-API-DMAC10.html)
WO (1) WO2017205684A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025228A2 (pt) * 2017-06-02 2020-06-23 Akarna Therapeutics, Ltd. Compostos bicíclicos fundidos
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
JP2022514731A (ja) * 2018-08-14 2022-02-15 アヴォリント 原発性硬化性胆管炎の処置方法
WO2020081766A1 (en) * 2018-10-18 2020-04-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
IL296100A (en) * 2020-03-11 2022-11-01 Dong A St Co Ltd A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
PE20231096A1 (es) 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao
US20240319210A1 (en) * 2020-12-18 2024-09-26 Human Metabolomics Institute, Inc. Application of neonatal biliary atresia biomarker and detection method for same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
ATE526318T1 (de) * 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
EP4137137A1 (en) * 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания

Also Published As

Publication number Publication date
MX2018014024A (es) 2019-08-29
BR112018073460A2 (pt) 2019-07-09
AU2017270221A1 (en) 2018-12-20
EP3463373A4 (en) 2020-04-22
WO2017205684A1 (en) 2017-11-30
CN109843298A (zh) 2019-06-04
SG10202011660RA (en) 2020-12-30
JP2019517478A (ja) 2019-06-24
KR20190040936A (ko) 2019-04-19
EP3463373A1 (en) 2019-04-10
RU2018145776A3 (cg-RX-API-DMAC10.html) 2021-03-01
CA3025007A1 (en) 2017-11-30
RU2018145776A (ru) 2020-06-26
US20200397798A1 (en) 2020-12-24
SG11201810290WA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
SG10202011660RA (en) Combination therapies with farnesoid x receptor (fxr) modulators
IL282391A (en) Allosteric modulators of hepatitis B core protein
IL274407A (en) Combined treatments
ZA201802901B (en) Farnesoid x receptor modulators
IL264951B (en) Positive allosteric modulators of the m1 muscarinic receptor
ZA201605712B (en) Therapeutic combinations with estrogen receptor modulators
IL261807A (en) Allosteric modulators of nicotinic acetylcholine receptors
IL286107A (en) Spiro-lactam nmda receptor modulators and uses thereof
ZA201700342B (en) Novel glp-1 receptor modulators
SG10201912456RA (en) Combination therapies
EP3423094A4 (en) GFRAL RECEPTOR THERAPIES
SI3166607T1 (sl) Modulatorji toličnih receptorjev za zdravljenje HIV-a
IL251067A0 (en) p2x7 modulators
GB201604070D0 (en) On-premise and off-premise communication
IL252565B (en) New receptor modulators
IL249203B (en) Androgen receptor modulators and methods of using them
ZA201708108B (en) Muscarinic m1 receptor positive allosteric modulators
HK40006535A (en) Combination therapies with farnesoid x receptor (fxr) modulators